Value Situations' Conor Maguire shares Marlowe plc $MRL.L thesis + TIC segment catalyst

Episode Summary

Executive Summary: The episode analyzes Marlowe (LSE: MRL), a UK small-cap serial acquirer in testing, inspection, certification, and GRC. Connor argues the stock is deeply undervalued versus peers and private-market comps, with a possible TIC sale and eventual GRC rerating creating multiple catalysts. The main debate centers on whether reported earnings are trustworthy and whether the business truly converts to cash.

Main Topics: Marlowe’s business model and market position: Marlowe is presented as a serial acquirer operating two complementary segments: TIC (fire safety, security, water and air testing) and GRC (HR, compliance, data management). The company serves regulated, recurring, business-critical needs across UK customers. Valuation discount versus peers and private-market comps: Connor argues Marlowe trades at a material discount to both listed peers and private-market valuations, making the current share price attractive even without a sale. Potential sale of the TIC division as a catalyst: Media reports suggest management explored selling the larger TIC division. A successful sale could monetize more than half the business and leave the higher-margin GRC arm effectively undervalued or even 'free.' Bear case: adjustments, cash flow, and roll-up risk: The main bearish critique is that heavy adjusted earnings add-backs and weak headline free cash flow resemble failed roll-ups. Connor responds that much of the cash leak comes from acquisition/integration costs that should fade over time. Management incentives and ownership alignment: The discussion emphasizes Lord Ashcroft’s ownership, CEO Alex Dacre’s below-market compensation, and a TSR-based incentive structure that only pays if shareholders do well, aligning management with equity holders. Capital allocation and future use of cash: If the TIC business is sold, Marlowe could generate a large cash pile, enabling buybacks, special distributions, or further acquisitions. The discussion notes leverage is conservative and equity issuance has historically funded larger deals. Macro view: 'real assets' and inflation-resilient businesses: Connor frames Marlowe as part of a broader preference for real-economy, regulation-driven, inflation-resilient assets that can reprice with costs and maintain demand in a higher-inflation world.

Key Arguments: Marlowe is a business-critical, recurring-revenue platform serving mandated compliance needs, which supports resilience and pricing power. The company has delivered on strategic targets: roughly 500m in run-rate revenue and 100m in run-rate EBITDA, despite market skepticism. At around 7.5x run-rate EBITDA, Marlowe is cheap versus listed peers (~16x), historic trading multiples (~20x), and private-market comps (15-33x). A TIC sale at or near the reported 650m pounds would exceed the current market cap, effectively leaving GRC undervalued or 'free.' Much of the low headline free cash flow is explained by one-off acquisition and restructuring costs; if those fade, cash generation should improve materially. Management appears economically incentivized to maximize equity value via a liquidity event, not to maximize salary or sit on assets indefinitely. Route density and cross-selling create operational leverage, helping drive organic growth and margins in a fragmented, regulated services market. The principal risk is not business quality but whether the contemplated transaction catalyst happens on the expected timeline and valuation terms.

Data Points: Market cap: ~£580 million - Approximate valuation of Marlowe on the AIM exchange Market cap (USD equivalent): ~$720 million - Rough US dollar equivalent cited in the discussion Revenue mix: ~60% TIC / ~40% GRC - Segment split by revenue and similarly by EBITDA contribution Organic revenue growth: ~8% to 10% - Underlying organic growth across the business Revenue CAGR: ~38% over the last five years - Headline growth driven by serial acquisitions Target run-rate revenue: £500 million - Management target that the company has now effectively reached Target run-rate EBITDA: £100 million - Management target that the company has now effectively reached LTM EBITDA multiple: ~9x - Current trading multiple cited by Connor Run-rate EBITDA multiple: ~7.5x - Adjusted for full-year effect of recent acquisitions Listed peer multiple: ~16x LTM EBITDA - UK and European public comparables Historic multiple: ~20x EBITDA - Marlowe’s own average valuation over the last five years Private-market comps: ~15x to 33x EBITDA - Comparable transaction valuations mentioned Potential TIC sale value: >£600 million - Estimated value of the TIC business, even after taxes/leakage GRC margin: ~25% to 30% EBITDA margin - Higher-margin profile of the GRC segment TIC margin: ~13% to 15% EBITDA margin - Lower-margin profile of the TIC segment SaaS share of GRC revenue: ~25% - Approximate SaaS component within GRC Customers: ~50,000 - Customer base across the business Recurring revenue: ~85% - Headline recurring revenue proportion across the business Target leverage: ~2.0x net debt / EBITDA - Management’s stated conservative leverage posture Capex: ~£16 million - Referenced against ~£84 million reported EBITDA Reported adjusted EBITDA: ~£83 million - FY23 reported figure referenced in the bear-case discussion Reported free cash flow to equity: ~£6 million - Headline cash flow outcome that bears criticize Stabilized free cash flow to equity: ~£30 million - Connor’s estimate after adding back restructuring costs on FY23-type earnings Run-rate free cash flow to equity: ~£43 million - Connor’s estimate on a ~£100 million EBITDA run rate Free cash flow yield: ~6% to 8% - Yield implied by stabilized and run-rate cash flow estimates Acquisition average ticket size: ~£8 million - Average size of prior bolt-on acquisitions Average acquisition multiple: ~7x EBITDA pre-synergies - Rule-of-thumb acquisition pricing cited from 2022 Post-synergy multiple: ~5.5x EBITDA - Illustrates value creation from integration and cost takeout Management TSR incentive: 10% of total shareholder return over a 10% hurdle by April 2026 - Long-term incentive plan for CEO and senior management Share price hurdle: ~11.1p per share - Implied threshold from the current ~6p stock price to trigger TSR incentives Acquisition funding mix: ~80% via new equity placings over the last five years - Historical funding pattern for larger acquisitions

Pivotal Quotes: "This business could be sitting on its own market cap in cash in 12 months' time or within the next 12 months." — Connor: Explaining why a TIC sale could materially re-rate the equity "You have to believe management's adjusted numbers to get comfortable or to believe in the story, because otherwise, when you look at EBITDA down to free cash flow, it doesn't really generate any cash." — Connor: Summarizing the core bear thesis "I think this is this falls into that sweet spot for a middle market private equity with a private credit lender providing the debt." — Connor: Why Marlowe could fit a sponsor-led takeout

Implications: If the TIC sale or a broader re-rating occurs, Marlowe could narrow the gap between market price and estimated intrinsic value. The episode suggests UK small-cap, compliance-driven compounders may be overlooked despite solid economics and catalyst potential.